Bisphosphonates in cancer therapy

Cancer Letters

Volumn 257, Issue 1, 2007, Pages 16-35

  Stresing, Verena ^a,b   Daubiné, Florence ^a,b   Benzaid, Ismahène ^a,b   Mönkkönen, Hannu ^a,b   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Bisphosphonate; Bone; Cancer; Metastasis

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ALENDRONIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUINDOSTATIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IBANDRONIC ACID; IMATINIB; INCADRONIC ACID; METHOTREXATE; MINODRONIC ACID; NE 6790; PACLITAXEL; PAMIDRONIC ACID; RETINOIC ACID; RISEDRONIC ACID; SIMVASTATIN; TAXANE DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; SHORT SURVEY; SINGLE DRUG DOSE; T LYMPHOCYTE;

EID: 34648828862     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.007     Document Type: Review

References (143)

1. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
2. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12 (2006) 6222s-6230s
3. McTaggart S.J. Isoprenylated proteins. Cell. Mol. Life Sci. 63 (2006) 255-267
4. Clezardin P., Ebetino F.H., and Fournier P.G.J. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 65 (2005) 4971-4974
5. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., and Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer 13 (2006) 7-26
6. Clézardin P., Fournier P., Boissier S., and Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr. Med. Chem. 10 (2003) 173-180
7. Green J. Antitumor effects of bisphosphonates. Cancer 97 (2003) 840-847
8. Verdijk R., Franke H.R., Wolbers F., and Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett. 246 (2007) 308-312
9. Sato K., Yuasa T., Nogawa M., Kimura S., Segawa H., Yokota A., and Maekawa T. A third-generation bisphosphonate (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br. J. Cancer 95 (2006) 1354-1361
10. Hirata J., Kikuchi Y., Kudoh K., Kita T., and Seto H. Inhibitory effects of bisphosphonates on the proliferation of human ovarian cancer cell lines and the mechanism. Med. Chem. 2 (2006) 223-226
11. Wada A., Fukui K., Sawai Y., Imanaka K., Kiso S., Tamura S., et al. Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J. Hepatol. 44 (2006) 142-150
12. Chuah C., Barnes D.J., Kwok M., Corbin A., Deininger M.W., Druker B.J., and Melo J.V. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia 19 (2005) 1896-1904
13. Inoue R., Matsuki N.A., Jing G., Kanematsu T., Abe K., and Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NfkappaB pathway in osteosarcoma cells. Br. J. Pharmacol. 146 (2005) 633-641
14. Yamagishi S., Abe R., Inagaki Y., Nakamura K., Sugawara H., Inokuma D., et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am. J. Pathol. 165 (2004) 1865-1874
15. Senaratne S.G., Mansi J.L., and Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer 87 (2002) 1340
16. Pandha H., Birchall L., Meyer B., Wilson N., Relph K., Anderson C., and Harrington K. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J. Urol. 176 (2006) 2255-2261
17. Kuroda J., Kimura S., Segawa H., Sato K., Matsumoto S., Nogawa M., et al. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci. 95 (2004) 186-192
18. Ory B., Blanchard F., Battaglia S., Gouin F., Redini F., and Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease. Mol. Pharmacol. 71 (2007) 333-343
19. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsäläinen J., and Mönkkönen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147 (2006) 437-445
20. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Mönkkönen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61 (2002) 1255-1262
21. H. Mönkkönen, P. Ottewell, I. Holen, A. Evans, D. Lefley, J. Kuokkanen, et al., Zoledronic acid induced IPP/ApppI accumulation in different cancer cell lines and in vivo, in: VI International Conference on Cancer-Induced Bone Disease (CIBD) San Antonio, Texas, USA, December 10-14, 2006.
22. Flach J., Antoni I., Villemin P., Bentzen C.L., and Niesor E.J. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem. Biophys. Res. Commun. 270 (2000) 240-246
23. Lowe L.C., Senaratne S.G., and Colston K.W. Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation. Biochem. Biophys. Res. Commun. 329 (2005) 772-779
24. Pourpak A., Dorr R.T., Meyers R.O., Powell M.B., and Stratton S.P. Cytotoxic activity of apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma call line. Invest. New Drugs 25 (2007) 107-114
25. Kubista B., Trieb K., Sevelda F., Toma C., Arrich F., Heffeter P., et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J. Orthop. Res. 24 (2006) 1145-1152
26. Iguchi T., Miyakawa Y., Yamamoto K., Kizaki M., and Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell. Signal. 15 (2003) 719-727
27. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 59 (2001) 193-202
28. Fidler I.J., and Hart I.R. Biological diversity in metastatic neoplasms, origins and implications. Science 217 (1982) 998-1003
29. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
30. Orr F.W., Wang H.H., Lafrenie R.M., Scherbarth S., and Nance D.M. Interactions between cancer cells and the endothelium in metastasis. J. Pathol. 190 (2000) 310-329
31. Westermark J., and Kähäri V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13 (1999) 781-792
32. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Löwik C., and Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98 (1996) 698-705
33. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., and Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57 (1997) 3890-3894
34. Coxon J.P., Oades G.M., Kirby R.S., and Colston K.W. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 94 (2004) 164-170
35. Caron E. Cellular functions of Rap1 GTP-binding protein: a pattern emerges. J. Cell Sci. 116 (2003) 435-440
36. Corso A., Ferretti E., Lunghi M., Zappasodi P., Mangiacavalli S., De Amici M., et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma. Cancer 104 (2005) 118-125
37. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
38. Miwa S., Mizokami A., Keller E.T., Taichman R., Zhang J., and Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res. 65 (2005) 8818-8825
39. Muller S., Migianu E., Lecouvey M., Kraemer M., and Oudar O. Alendronate inhibits proliferation and invasion of epidermoid carcinoma cells in vitro. Anticancer Res. 25 (2005) 2655-2660
40. Denoyelle C., Hong L., Vannier J.P., Soria J., and Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br. J. Cancer 88 (2003) 1631-1640
41. Cheng Y.Y., Huang L., Lee K.M., Li K., and Kumta S.M. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr. Blood Cancer 42 (2004) 410-415
42. Hashimoto K., Morishige K., Sawada K., Tahara M., Kawagishi R., Ikebuchi Y., et al. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res. 65 (2005) 540-545
43. Montague R., Hart C., George N., Ramani V., Brown M., and Clarke N. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur. Urol. 46 (2004) 389-402
44. Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin. Oncol. 28 (2001) 35-44
45. Brown J.E., Neville-Webbe H., and Coleman R.E. The role of bisphosphonates in breast and prostate cancer. J. Clin. Oncol. 18 (2004) 1378-1391
46. Corey E., Brown L.G., and Quinn J.E. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. 9 (2003) 295-306
47. Yaccoby S., Pearse R.N., Johnson C.L., Barlogie B., Choi Y., and Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 116 (2002) 278-290
48. Croucher P.I., de Hendrik R., Perry M.J., Hijzen A., Shipman C.M., Lippitt J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 18 (2003) 482-492
49. Zhou Z., Guan H., Duan X., and Kleinerman E.S. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104 (2005) 1713-1720
50. Ory B., Heymann M.F., Kamijo A., Gouin F., Heymann D., and Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104 (2005) 2522-2529
51. Gouin F., Ory B., Redini F., and Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int. J. Cancer 119 (2006) 980-984
52. Daubiné F., Le Gall C., Gasser J., Green J., and Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl. Cancer Inst. 99 (2007) 322-330
53. Giraudo E., Inoue M., and Hanahan D. An aminobisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114 (2004) 623-633
54. Matsumoto S., Kimura S., Segawa H., Kuroda J., Yuasa T., Sato K., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
55. Wakchoure S., Merrell M.A., Aldrich W., Millender-Swain T., Harris K.W., Triozzi P., and Selander K.S. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res. 12 (2006) 2862-2868
56. Merrell M.A., Wakchoure S., Ilvesaro J.M., Zinn K., Gehrs B., Lehenkari P.P., et al. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells. Eur. J. Pharmacol. 559 (2007) 21-31
57. Ylitalo R., Mönkkönen J., Urtti A., and Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J. Lab. Clin. Med. 127 (1996) 200-206
58. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55 (1995) 3551-3557
59. Hiraga T., Williams P.J., Mundy G.R., and Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231human breast cancer cells in bone metastases. Cancer Res. 61 (2001) 4418-4424
60. Zhang H., Yano S., Miki T., Goto H., Kanematsu T., Muguruma H., et al. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung-cancer cells in NK-cell depleted SCID mice. Clin. Exp. Metastasis 20 (2003) 153-159
61. Michigami T., Hiraga T., and Williams P.J. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res. Treat. 75 (2002) 249-258
62. Hiraga T., Williams P.J., Ueda A., Tamura D., and Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 10 (2004) 4559-4677
63. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J. Suppl. 2 (2000) 134-141
64. Lyden D., Koichi H., Diass S., Costas C., Blaikie P., Butrosi L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
65. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., and Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62 (2002) 6538-6544
66. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302 (2002) 1055-1061
67. Bezzi M., Hasmim M., Bieler G., Dormond O., and Rüegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death. J. Biol. Chem. 278 (2003) 43603-43614
68. Hashimoto K., Morishige K., Sawada K., Tahara M., Shimizu S., Ogata S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Commun. 354 (2007) 478-484
69. Santini D., Vincenzi B., Dicuonzo G., Avvisati G., Massacesi C., Battistoni F., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9 (2003) 2893-2897
70. Vincenzi B., Santini D., Dicuonzo G., Battistoni F., Gavasci M., La Cesa A., et al. Zoledronic-acid related angiogenesis modifications and survival in advanced breast cancer patients. J. Interferon Cytokine Res. 25 (2005) 144-151
71. Kunzmann V., Bauer E., Feurle J., Weißinger F., Tony H.P., and Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96 (2000) 384-392
72. Miyagawa F., Tanaka Y., Yamashita S., and Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδT cells by aminobisphosphonate antigen. J. Immunol. 166 (2001) 5508-5514
73. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., et al. Induction of γδT-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102 (2003) 2310-2311
74. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger T., and Tony H.P. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102 (2003) 200-206
75. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif. Tissue Int. 75 (2004) 451-461
76. Sanders J.M., Ghosh S., Chan J.M.W., Meints G., Wang H., Raker A.M., et al. Quantitative structure-activity relationships for T cell activation by bisphosphonates. J. Med. Chem. 47 (2004) 375-384
77. Ferrarini M., Ferrero E., Dagna L., Poggi A., and Zocchi M.R. Human γδ T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol. 23 (2002) 14-18
78. Kato Y., Tanaka Y., Tanaka H., Yamashita S., and Minato N. Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate. J. Immunol. 170 (2003) 3608-3613
79. Sicard H., Al Saati T., Delsol G., and Fournie J.J. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol. Med. 7 (2001) 711-722
80. Bukowski J.F., Morita C.T., Tanaka Y., Bloom B.R., Brenner M.B., and Band H. V gamma 2V delta TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 154 (1995) 998-1006
81. Sato K., Kimura S., Segawa H., Yokota A., Matsumoto S., Kuroda J., et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116 (2005) 94-99
82. Kabelitz D., Wesch D., Pitters E., and Zöller M. Characterization of tumor reactivity of human Vγ9Vδ2 T cells in vitro and in SCID mice in vivo. J. Immunol. 173 (2004) 6767-6776
83. Lozupone F., Pende D., Burgio V.L., Castelli C., Spada M., Venditti M., et al. Effect of human natural killer and γδ T cells on the growth of human antologous melanoma xenografts in SCID mice. Cancer Res. 64 (2004) 378-385
84. Zheng B.J., Chan K.W., Im S., Chua D., Sham J.S., Tin P.C., et al. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int. J. Cancer 92 (2001) 421-425
85. Wolf A.M., Rumpold H., Tilg H., Gastl G., and Gunsilius E. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91 (2006) 1165-1171
86. Viey E., Laplace C., and Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 5 (2005) 973-986
87. Kabelitz D., Wesch D., and He W. Perspectives of γδ T cells in tumor immunology. Cancer Res. 67 (2007) 5-8
88. Green A.E., Lissina A., Hutchinson S.L., Hewitt R.E., Temple B., James D., et al. Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin. Clin. Exp. Immunol. 136 (2004) 472-482
89. Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. J. Invest. Dermatol. 126 (2006) 25-31
90. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor γδ T cells γδ recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197 (2003) 163-168
91. Spada F.M., Grant E.P., Peters P.J., Sugita M., Melian M., and Leslie D.S. Selfrecognition of CD1 by gamma/delta T cells: implications for innate immunity. J. Exp. Med. 191 (2000) 937-948
92. Girlanda S., Fortis C., Belloni D., Ferrero E., Ticozzi P., Sciorati C., et al. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res. 65 (2005) 7502-7508
93. Corvaisier M., Moreau-Aubry A., Diez E., Bennouna J., Mosnier J.F., Scotet E., et al. V gamma9V delta 2 T cell response to colon carcinoma cells. J. Immunol. 175 (2005) 5481-5488
94. Rincon-Orozco B., Kunzmann V., Wrobel P., Kabelitz D., Steinle A., and Herrmann T. Activation of V gamma 9V delta 2 T cells by NKG2D. J. Immunol. 175 (2005) 2144-2151
95. Scotet E., Martinez L.O., Grant E., Barbaras R., Jeno P., Guiraud M., et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-released structure and apolipoprotein A-I. Immunity 22 (2005) 71-80
96. Bonneville M., and Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18 (2006) 539-546
97. Bowen M.A., Aruffo A.A., and Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins 40 (2000) 420-428
98. van Kempen L.C., van den Oord J.J., van Muijen G.N., et al. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am. J. Pathol. 156 (2000) 769-774
99. Weichert W., Knosel T., Bellach J., Dietel M., and Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J. Clin. Pathol. 57 (2004) 1160-1164
100. Kristiansen G., Pilarsky C., Wissmann C., et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J. Pathol. 205 (2005) 359-376
101. Burkhardt M., Mayordomo E., Winzer K.-J., Fritzsche F., Gansukh T., Pahl S., et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J. Clin. Pathol. 59 (2006) 403-409
102. Tomita K., van Bokhoven A., Jansen C.F., et al. Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem. Biophys. Res. Commun. 267 (2000) 870-874
103. Kato Y., Tanaka Y., Hayashi M., Okawa K., and Minato N. Involvement of CD166 in the activation of human gamma delta t cells by tumor cells sensitized with nonpeptide antigens. J. Immunol. 177 (2006) 877-884
104. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., Arcara C., Valerio M.R., Meraviglia S., Di Sano C., Sireci G., and Salerno A. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102 (2003) 2310-2311
105. Gioia C., Agrati C., Casetti R., et al. Lack of CD45RA-CD27-Vγ9Vδ2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J. Immunol. 168 (2002) 1484-1489
106. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., and Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41 (1987) 326-331
107. Thompson K., Rojas-Navea J., and Rogers M.J. Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 107 (2006) 651-654
108. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84 (2001) 1126-1134
109. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., and Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int. J. Cancer 113 (2005) 364-371
110. Neville-Webbe H.L., Evans C.A., Coleman R.E., and Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 27 (2006) 92-103
111. Woodward J.K.L., Neville-Webbe H.L., Coleman R.E., and Holen I. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 16 (2005) 845-854
112. Olsen S.R. Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. Biomed. Pharmacother. 59 Suppl 2 (2005) 306-310
113. Witters L.M., Crispino J., Fraterrigo T., Green J., and Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cells. Am. J. Clin. Oncol. 26 (2003) 92-97
114. Horie N., Murata H., Kimura S., Takeshita H., Sakabe T., Matsui T., et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br. J. Cancer 96 (2007) 255-261
115. Benassi M.S., Chiechi A., Ponticelli F., Pazzaglia L., Gamberi G., and Zanella L. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 250 (2007) 194-205
116. Yata K., Otsuki T., Yamada O., Wada H., Yawata Y., and Sugihara T. Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells. Int. J. Hematol. 75 (2002) 534-539
117. Otsuki T., Sakaguchi H., Hatayama T., Fujii T., Tsujioka T., Sugihara T., et al. Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells. Oncol. Rep. 11 (2004) 1053-1058
118. Cafforio P., Dammacco F., Gernone A., and Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26 (2005) 883-891
119. Schmidmaier R., Simsek M., Baumann P., Emmerich B., and Meinhardt G. Synergistic anti-myeloma effects of zoledronate and Simvastatin. Anticancer Drugs 17 (2006) 621-629
120. Kuroda J., Kimura S., Segawa H., Kobayashi Y., Yoshikawa T., Urasaki Y., et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102 (2003) 2229-2235
121. Kimura S., Kuroda J., Segawa H., Sato K., Nogawa M., Yuasa T., Ottmann O.G., and Maekawa T. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int. J. Hematol. 79 (2004) 37-43
122. Caraglia M., D'Alessandro A.M., Marra M., Giuberti G., Vitale G., Viscomi C., et al. The farnesyl transferase inhibitor R115777 (Zarnestras) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 23 (2004) 6900-6913
123. Tamanoi F., Gau C.-L., Jiang C., Edamatsu H., and Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell. Mol. Life Sci. 58 (2001) 1636-1649
124. Hiraga T., Ueda A., Tamura D., Hata K., Ikeda F., Williams P.J., et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int. J. Cancer 106 (2003) 973-979
125. Uehara H., Kim S.J., Karashima T., Shepherd D.L., Fan D., Tsan R., et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 95 (2003) 558-570
126. Kim S.J., Uehara H., Yazici S., He J., Langley R.R., Mathew P., et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res. 65 (2005) 3707-3715
127. Heymann D., Ory B., Blanchard F., Heymann M.F., Coipeau P., Charrier C., et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37 (2005) 74-86
128. Inoue K., Karashima T., Fukata S., Nomura A., Kawada C., Kurabayashi A., et al. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin. Cancer Res. 11 (2005) 6669-6677
129. Melisi D., Caputo R., Damiano V., Bianco R., Veneziani B.M., Bianco A.R., et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr. Relat. Cancer 12 (2005) 1051-1058
130. Tortora G., Caputo R., Damiano V., Melisi D., Bianco R., Fontanini G., et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin. Cancer Res. 9 (2003) 1566-1572
131. Segawa H., Kimura S., Kuroda J., Sato K., Yokota A., Kawata E., et al. Zoledronate synergises with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth. Br. J. Haematol. 130 (2005) 558-560
132. Ottewell P.D., Jones M., Coleman R.E., and Holen I. Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo. Breast Cancer Res. 100 S1 (2006) 5290
133. Hillner B.E., Ingle J.N., Berenson J.R., Janjan N.A., Albain K.S., Lipton A., et al. American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18 (2000) 1378-1391
134. van der Pluijm G., Que I., Sijmons B., Buijs J.T., Lowik C.W., Wetterwald A., et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 65 (2005) 7682-7690
135. Gao L., Deng H., Zhao H., Hirbe A., Harding J., Ratner L., and Weilbaecher K. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106 (2005) 4294-4302
136. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and leukemia group B trial 9741. J. Clin. Oncol. 21 (2003) 1431-1439
137. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60 (2000) 2949-2954
138. Fournier P., Daubiné F., Lundy M.W., Ebetino F.H., and Clézardin P. The direct antitumour activity of bisphosphonates in vivo depends on their bone mineral affinity. Bone 38 (2006) S45
139. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjällman A.H.M., Ballmer-Hofer K., and Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (2006) 272-281
140. Vogt U., Bielawski K.P., Bosse U., and Schlotter C.M. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol. Rep. 12 (2004) 1109-1114
141. Ullen A., Lennartsson L., Harmenberg U., Hjelm-Eriksson M., Kalkner K.M., Lennernas B., and Nilsson S. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol. 44 (2005) 644-650
142. Budman D.R., and Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70 (2006) 147-153
143. Tassone P., Forciniti S., Galea E., Morrone G., Turco M.C., Martinelli V., Tagliaferri P., and Venuta S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14 (2000) 841-844